Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Sharkey

Showing results (91-100 of 145) with videos related to

Pageof 15
Sort By:
Cancer Treatment and Research|January 1, 1990
In-vivo antibody imaging for the detection of human tumorsD M Goldenberg, H Goldenberg, R M Sharkey, et al.
Cancer Research|August 1, 1996
Antibody penetration of tumor GS-7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colonR D Blumenthal, R Stein, R M Sharkey, et al.
Bioconjugate Chemistry|July 1, 1997
Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent developmentH Karacay, R M Sharkey, S V Govindan, et al.
Nuclear Medicine Communications|February 9, 1999
In vivo stability and metabolism of 99Tcm-labelled anti-CD4 monoclonal antibodies and Fab' fragmentsR W Kinne, K Schemer, T Behr, et al.
Cancer Research|February 1, 1990
Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibodyJ A Siegel, D A Pawlyk, R E Lee, et al.
New Jersey Medicine : the Journal of the Medical Society of New Jersey|November 1, 1990
Monoclonal antibody therapy of cancerD M Goldenberg, R M Sharkey, H Goldenberg, et al.
Cancer Research|January 1, 1986
Quantitative whole-body autoradiography of radiolabeled antibody distribution in a xenografted human cancer modelI Fand, R M Sharkey, W P McNally, et al.
Bioconjugate Chemistry|September 19, 2002
Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigenH Karacay, R M Sharkey, W J McBride, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragmentsS O Leung, Z Qu, H J Hansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphomaM E Juweid, E Stadtmauer, G Hajjar, et al.
Pageof 15

Showing results (91-100 of 145) with videos related to

Sort By:
Pageof 15
Cancer Treatment and Research|January 1, 1990
In-vivo antibody imaging for the detection of human tumorsD M Goldenberg, H Goldenberg, R M Sharkey, et al.
Cancer Research|August 1, 1996
Antibody penetration of tumor GS-7 xenografts in nude mice: a model for mucinous adenocarcinoma of the colonR D Blumenthal, R Stein, R M Sharkey, et al.
Bioconjugate Chemistry|July 1, 1997
Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent developmentH Karacay, R M Sharkey, S V Govindan, et al.
Nuclear Medicine Communications|February 9, 1999
In vivo stability and metabolism of 99Tcm-labelled anti-CD4 monoclonal antibodies and Fab' fragmentsR W Kinne, K Schemer, T Behr, et al.
Cancer Research|February 1, 1990
Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibodyJ A Siegel, D A Pawlyk, R E Lee, et al.
New Jersey Medicine : the Journal of the Medical Society of New Jersey|November 1, 1990
Monoclonal antibody therapy of cancerD M Goldenberg, R M Sharkey, H Goldenberg, et al.
Cancer Research|January 1, 1986
Quantitative whole-body autoradiography of radiolabeled antibody distribution in a xenografted human cancer modelI Fand, R M Sharkey, W P McNally, et al.
Bioconjugate Chemistry|September 19, 2002
Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigenH Karacay, R M Sharkey, W J McBride, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragmentsS O Leung, Z Qu, H J Hansen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphomaM E Juweid, E Stadtmauer, G Hajjar, et al.
Pageof 15